Korro Bio (KRRO) Other Non-Current Assets (2018 - 2026)
Korro Bio's (KRRO) quarterly Other Non-Current Assets came in at $2.3 million in Q1 2026, down 26.06% YoY from $3.2 million in Q1 2025, and down 5.1% on a QoQ basis from $2.5 million in Q4 2025.
Korro Bio (KRRO) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Other Non-Current Assets data on file, last reported at $2.3 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 26.06% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 26.06% YoY) and the FY2025 annual result came in at $2.5 million, down 11.62% from the prior year.
- Other Non-Current Assets eased to $2.3 million in Q1 2026, from $2.5 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $3.4 million in Q1 2024 to a low of $228000.0 in Q4 2022.
- A 5-year average of $2.4 million and a median of $2.4 million in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets plunged 86.58% — and 2023, when it soared 1090.35%.
- Tracing KRRO's Other Non-Current Assets over 5 years: stood at $228000.0 in 2022, then soared by 1090.35% to $2.7 million in 2023, then rose by 3.06% to $2.8 million in 2024, then decreased by 11.62% to $2.5 million in 2025, then fell by 5.1% to $2.3 million in 2026.
- The last three Other Non-Current Assets figures came in at $2.3 million (Q1 2026), $2.5 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | 2.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.47 Mn |
| Mar 31, 2026 | 2.35 Mn |
| Dec 31, 2025 | 2.47 Mn |
| Sep 30, 2025 | 3.17 Mn |
| Jun 30, 2025 | 3.21 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Dec 31, 2024 | 2.80 Mn |
| Sep 30, 2024 | 2.11 Mn |
| Jun 30, 2024 | 3.41 Mn |
| Mar 31, 2024 | 3.41 Mn |
| Dec 31, 2023 | 2.71 Mn |
| Jun 30, 2023 | 1.96 Mn |
| Mar 31, 2023 | 1.70 Mn |
| Dec 31, 2022 | 228,000.00 |
| Sep 30, 2022 | 1.70 Mn |
| Jun 30, 2022 | 1.70 Mn |
| Mar 31, 2022 | 1.70 Mn |
| Dec 31, 2021 | 1.70 Mn |
| Sep 30, 2021 | 1.73 Mn |
| Jun 30, 2021 | 1.83 Mn |